May 10, 2023 Pharmacy Benefits Management Program – Reimbursement for Clotting Factor LAC 50:XXIX.949

Back to Main Notices of Intent Page

Back to Rulemaking Home Page

Amends the provisions governing methods of payment in the Pharmacy Benefits Management Program in order to: 1) change the reimbursement methodology for clotting factor products to a state generated actual acquisition cost ingredient cost and a unit based professional dispensing fee; and 2) limit clotting factor products to pharmacy claims only, in compliance with U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services requirements.

Contact Information:  Tara A. LeBlanc, Bureau of Health Service Financing, P.O. Box 91030, Baton Rouge, LA 70821-9030

Act 401 Compliance:  The Notices of Intent pages were developed in accordance with ACT 401 of the 2014 Louisiana Legislative Session.

Disclaimer:  Please note that the official versions of the Notices of Intent are maintained by the Office of State Register’s website at http://www.doa.louisiana.gov/osr/osr.htm.  The excerpted versions of these Notices of Intent contained on this website are provided as a courtesy service to the public and is unofficial and should not be regarded as such. Users are encouraged to visit the Office of State Register’s website for the official version.

RELATED ITEMS

• Emergency Rule: N/A
• Notice of Intent: Prior to Proposed Rule: March 2023 LAC
• Notice of Intent: Proposed Rule
• Notice of Intent: May 20, 2023 (Louisiana Register)